The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept

Overview

Journal Mol Diagn Ther

Specialties Molecular Biology
Pathology
Pharmacology

Date 2018 Jun 27

PMID 29943154

Citations 6

Authors

M Guarene

A Pasi

V Bolcato

R Cananzi

A Piccolo

I Sbarsi

C Klersy

R Cacciatore

Valeria Brazzelli

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis is an immune-mediated dermatosis with a wide genetic predisposition. The immunogenetic background, specifically interactions between human leukocyte antigen (HLA) class I ligands and killer-cell immunoglobulin-like receptor (KIRs), have functional significance in modulating natural killer (NK) cells and can influence susceptibility and response to biological therapy.

Objective: The main aim of this study was to correlate HLA-A and -B KIR ligands with response to biological therapy in patients with psoriasis.

Methods: HLA-A and -B polymorphisms were determined in 48 patients (35 males and 13 females), with a mean of 22 years of disease (range 8-55). All patients were treated with biological therapy (adalimumab, etanercept, infliximab, or ustekinumab) for at least 6 months.

Results: This study identifies, with statistical significance, the presence of at least one ligand HLA-A Bw4-80I in the "poor-responder" population (patients who needed two or more biologics) compared with the "responder" population (patients with good response after a single biological drug) (47.62 vs. 11.11%; p = 0.006) as well as in "non-responders to etanercept" compared with "responders to etanercept" (52.63 vs. 5%; p = 0.001).

Conclusion: Our preliminary results suggest that at least one ligand HLA-A Bw4-80I could be associated with "difficult-to-treat" psoriasis and that this ligand may reduce the probability of response to etanercept, producing more tumor necrosis factor (TNF)-α and neutralizing NK activity through a predominance of activating KIR. The ab initio identification of genetic markers of response to biologic therapy could improve the efficacy and economic impact of these agents.

Citing Articles

Evidence-based modalities in the management of Psoriasis and Psoriatic arthritis.

Francesco C Bioinformation. 2023; 19(6):679-684.

PMID: 37885781 PMC: 10598368. DOI: 10.6026/97320630019679.

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.

Berna-Rico E, Perez-Bootello J, Abbad-Jaime de Aragon C, Gonzalez-Cantero A Int J Mol Sci. 2023; 24(12).

PMID: 37372997 PMC: 10298473. DOI: 10.3390/ijms24129850.

Reinforcing involvement of NK cells in psoriasiform dermatitis animal model.

Surcel M, Munteanu A, Huica R, Isvoranu G, Pirvu I, Constantin C Exp Ther Med. 2019; 18(6):4956-4966.

PMID: 31798717 PMC: 6880363. DOI: 10.3892/etm.2019.7967.

HLA Correlations with Clinical Phenotypes and Risk of Metabolic Comorbidities in Singapore Chinese Psoriasis Patients.

Shen M, Lim S, Tan E, Oon H, Ren E Mol Diagn Ther. 2019; 23(6):751-760.

PMID: 31473973 DOI: 10.1007/s40291-019-00423-z.

Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients.

Zalzala H, Abdullah G, Abbas M, Mohammedsalih H, Mahdi B Saudi Med J. 2018; 39(9):886-890.

PMID: 30251731 PMC: 6201012. DOI: 10.15537/smj.2018.9.23156.

References

Nast A, Gisondi P, Ormerod A, Saiag P, Smith C, Spuls P . European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015; 29(12):2277-94. DOI: 10.1111/jdv.13354. View

Colucci F, Traherne J . Killer-cell immunoglobulin-like receptors on the cusp of modern immunogenetics. Immunology. 2017; 152(4):556-561. PMC: 5680062. DOI: 10.1111/imm.12802. View

Murdaca G, Gulli R, Spano F, Lantieri F, Burlando M, Parodi A . TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014; 134(10):2503-2509. DOI: 10.1038/jid.2014.123. View

Galluzzo M, Andreani M, Testi M, Chimenti S, Talamonti M . HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. Mol Diagn Ther. 2016; 20(3):227-30. DOI: 10.1007/s40291-016-0199-y. View

Brazzelli V, Quaglini M, Martinetti M, Nolli G, Salvaneschi L, Cuccia M . A peculiar sequence motif in the alpha-1-domain of the HLA-C molecule in psoriasis. Dermatology. 2000; 200(2):99-103. DOI: 10.1159/000018338. View

Linares-Pineda T, Canadas-Garre M, Sanchez-Pozo A, Angel Calleja-Hernandez M . Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. Pharmacol Res. 2016; 113(Pt A):71-80. DOI: 10.1016/j.phrs.2016.07.020. View

Stuart P, Nair R, Tsoi L, Tejasvi T, Das S, Kang H . Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet. 2015; 97(6):816-36. PMC: 4678416. DOI: 10.1016/j.ajhg.2015.10.019. View

Kulkarni S, Martin M, Carrington M . The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008; 20(6):343-52. PMC: 3501819. DOI: 10.1016/j.smim.2008.06.003. View

Di Meglio P, Villanova F, Nestle F . Psoriasis. Cold Spring Harb Perspect Med. 2014; 4(8). PMC: 4109580. DOI: 10.1101/cshperspect.a015354. View

10.

Smith C, Jabbar-Lopez Z, Yiu Z, Bale T, Burden A, Coates L . British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017; 177(3):628-636. DOI: 10.1111/bjd.15665. View

11.

Talamonti M, DAdamio S, Bianchi L, Galluzzo M . The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. Mol Diagn Ther. 2017; 21(5):467-480. DOI: 10.1007/s40291-017-0274-z. View

12.

Papp K, Menter A, Strober B, Kricorian G, Thompson E, Milmont C . Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2015; 72(3):436-439.e1. DOI: 10.1016/j.jaad.2014.10.026. View

13.

Chen L, Tsai T . HLA-Cw6 and psoriasis. Br J Dermatol. 2017; 178(4):854-862. DOI: 10.1111/bjd.16083. View

14.

van Vugt L, van den Reek J, Coenen M, de Jong E . A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol. 2017; 178(1):86-94. DOI: 10.1111/bjd.15753. View

15.

Puig L, Julia A, Marsal S . The pathogenesis and genetics of psoriasis. Actas Dermosifiliogr. 2013; 105(6):535-45. DOI: 10.1016/j.ad.2012.11.006. View

16.

Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Puppo F . Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017; 16(10):1173-1179. DOI: 10.1080/14740338.2017.1361404. View